Review Article
Biomarkers in Colorectal Cancer Screening
Vijeta Pamudurthy1, Marc Bissonnette2 and Vani Konda2*1Department of Medicine, Riverside Medical Center, Kankakee, Illinois, USA
2Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois, USA
- *Corresponding Author:
- Vani Konda
Department of Medicine, Section
of Gastroenterology University of Chicago
Medical Center, Chicago, Illinois, USA
Tel: 773-702-1000
E-mail: vkonda@medicine.bsd.uchicago.edu
Received date: December 30, 2015 Accepted date: February 3, 2016 Published date: February 10, 2016
Citation: Pamudurthy V, Bissonnette M, Konda V (2016) Biomarkers in Colorectal Cancer Screening. J Gastrointest Dig Syst 6:389. doi:10.4172/2161-069X.1000389
Copyright: © 2016 Pamudurthy V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Colorectal cancer is the second most frequent cause of death by cancer. Current gold standard screening tools are invasive, expensive, and require a lot of preparation, which result in decreased patient compliance. Screening modalities that are less invasive, have high sensitivity and specificity, inexpensive, and more accepted by the general population than the current gold standard screening tools may potentially prevent the deaths caused by colorectal cancer. Noninvasive stool tests like fecal occult blood test and fecal immunohistochemical test have become widely used in detecting hemoglobin in stool. Some of these biomarkers have shown favorable results to detecting adenomas and early stage colorectal cancer diagnosis. Furthermore, the evolution of biomarkers is becoming more promising for the early diagnosis of colorectal cancer. This article will discuss the advances of biomarkers in stool, serum, and urine assays that enable early detection of colorectal cancer.
